Accelevir supports federally and globally funded programs through NIH, CEPI, and BARDA with specialized molecular and immunology assay platforms for infectious disease, vaccine, and therapeutic development.
- High-Containment Sample Processing – BSL-2+ workflows for viral vector and infectious pathogen handling.
- Multi-Species & Translational Capability – Rodent, NHP, and human assay platforms to bridge preclinical and clinical phases.
- Rapid Assay Deployment – Fit-for-purpose assays aligned to government program milestones and technical requirements.
- Experience in Pandemic & Emerging Pathogen Readiness – Validated workflows for HIV, SARS-CoV-2, influenza, and filoviruses.